BridgeBio Pharma, Inc. Other Executive Compensation Disclosures
Every other executive-compensation XBRL fact the company filed (policies, award timing, footnotes, adjustments), newest first. Long text is shortened; the filing has the full text.
- 2025-10-29: Disclosure Rule10b51Arr Terminated; Period 2025-07-01..2025-09-30; Value No.
- 2025-10-29: Disclosure Non Rule10b51Arr Adopted; Period 2025-07-01..2025-09-30; Value No.
- 2025-10-29: Disclosure Non Rule10b51Arr Terminated; Period 2025-07-01..2025-09-30; Value No.
- 2025-08-05: Disclosure Rule10b51Arr Adopted; Period 2025-04-01..2025-06-30; Value No.
| Filed | Disclosure | Qualifiers | Period | Value |
|---|---|---|---|---|
| 2025-10-29 10-Q | Rule10b51Arr Terminated | 2025-07-01..2025-09-30 | No | |
| 2025-10-29 10-Q | Non Rule10b51Arr Adopted | 2025-07-01..2025-09-30 | No | |
| 2025-10-29 10-Q | Non Rule10b51Arr Terminated | 2025-07-01..2025-09-30 | No | |
| 2025-08-05 10-Q | Rule10b51Arr Adopted | 2025-04-01..2025-06-30 | No | |
| 2025-08-05 10-Q | Non Rule10b51Arr Adopted | 2025-04-01..2025-06-30 | No | |
| 2025-08-05 10-Q | Rule10b51Arr Terminated | 2025-04-01..2025-06-30 | No | |
| 2025-08-05 10-Q | Non Rule10b51Arr Terminated | 2025-04-01..2025-06-30 | No | |
| 2025-08-05 10-Q | Material Terms Of Trading Arrangement | 2025-04-01..2025-06-30 | On May 8, 2025 , Dr. Charles J. Homcy , a member of our Board of Directors , adopted a trading plan (the “Homcy Trading Plan”) in tended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c) for the potential sale of a maximum of 300,000 shares of our common stock. … | |
| 2025-04-30 DEF 14A | Award Timing MNPI Disclosure | 2024-01-01..2024-12-31 | Equity Grant Practices We do not have a formal policy regarding the granting practices of our equity awards. We generally make refresh grants to existing employees in the first quarter of each year after our year end results are filed. However, our Board and Compensation Committee, as applicable, ca… | |
| 2025-04-30 DEF 14A | Award Timing Method | 2024-01-01..2024-12-31 | We do not have a formal policy regarding the granting practices of our equity awards. We generally make refresh grants to existing employees in the first quarter of each year after our year end results are filed. | |
| 2025-04-30 DEF 14A | Award Timing Predetermined | 2024-01-01..2024-12-31 | Yes | |
| 2025-04-30 DEF 14A | Award Timing How MNPI Considered | 2024-01-01..2024-12-31 | However, our Board and Compensation Committee, as applicable, carefully review any potential material nonpublic information before granting equity awards. We do not time our equity award grants either to take advantage of a depressed stock price, or an anticipated increase in stock price, and we hav… | |
| 2025-04-30 DEF 14A | Award Timing MNPI Considered | 2024-01-01..2024-12-31 | No | |
| 2025-04-30 DEF 14A | MNPI Disclosure Timed For Compensation Val | 2024-01-01..2024-12-31 | No | |
| 2025-04-30 DEF 14A | Insider Trading Policies Proc Adopted | 2024-01-01..2024-12-31 | Yes | |
| 2025-04-30 DEF 14A | Pay versus Performance Table | 2024-01-01..2024-12-31 | Pay-Versus-Performance The Compensation Committee approves and administers our executive compensation program, which it designs to attract, incentivize, reward, and retain our executive officers. Our program aligns executive pay with shareholder interests and links pay to performance through a blend… | |
| 2025-04-30 DEF 14A | Named Executive Officers Footnote | 2024-01-01..2024-12-31 | 1. The dollar amounts reported in column (b) represent the amount of total compensation reported for Dr. Kumar (our “PEO”) for each corresponding covered year in the “Total” column of the Summary Compensation Table for each applicable year. 3. The dollar amounts reported in column (d) represent the … | |
| 2025-04-30 DEF 14A | Adjustment To PEO Compensation Footnote | 2024-01-01..2024-12-31 | 2. The dollar amounts reported in column (c) represent the amount of “compensation actually paid” to Dr. Kumar, as computed in accordance with Item 402(v) of Regulation S-K for each covered fiscal year. The dollar amounts do not reflect the actual amount of compensation earned or received by or paid… | |
| 2025-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: EqtyAwrdsInSummryCompstnTblForAplblYr; ExecutiveCategory: Peo | 2024-01-01..2024-12-31 | -$13.54M |
| 2025-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTbl; ExecutiveCategory: Peo | 2024-01-01..2024-12-31 | -$4.70M |
| 2025-04-30 DEF 14A | Eqty Awrds Adjustment Footnote | 2024-01-01..2024-12-31 | (b) Equity values are calculated in accordance with FASB ASC Topic 718, and the valuation assumptions used to calculate fair values did not materially differ from those disclosed at the time of grant. The equity award adjustments for the listed fiscal year include the addition (or subtraction, as ap… | |
| 2025-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstd; ExecutiveCategory: Peo | 2024-01-01..2024-12-31 | $11.11M |
| 2025-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrs; ExecutiveCategory: Peo | 2024-01-01..2024-12-31 | -$10.75M |
| 2025-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYr; ExecutiveCategory: Peo | 2024-01-01..2024-12-31 | $1.72M |
| 2025-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYr; ExecutiveCategory: Peo | 2024-01-01..2024-12-31 | -$6.78M |
| 2025-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYr; ExecutiveCategory: Peo | 2024-01-01..2024-12-31 | $0.00 |
| 2025-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYr; ExecutiveCategory: Peo | 2024-01-01..2024-12-31 | $0.00 |
| 2025-04-30 DEF 14A | Adjustment To Non PEO NEO Compensation Footnote | 2024-01-01..2024-12-31 | 4. The dollar amounts reported in column (e) represent the average amount of “executive compensation actually paid” to our Non-PEO NEOs, as computed in accordance with Item 402(v) of Regulation S-K for each covered fiscal year. The dollar amounts do not reflect the actual average amount of compensat… | |
| 2025-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: EqtyAwrdsInSummryCompstnTblForAplblYr; ExecutiveCategory: NonPeoNeo | 2024-01-01..2024-12-31 | -$5.02M |
| 2025-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTbl; ExecutiveCategory: NonPeoNeo | 2024-01-01..2024-12-31 | -$1.33M |
| 2025-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstd; ExecutiveCategory: NonPeoNeo | 2024-01-01..2024-12-31 | $4.22M |
| 2025-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrs; ExecutiveCategory: NonPeoNeo | 2024-01-01..2024-12-31 | -$4.04M |
| 2025-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYr; ExecutiveCategory: NonPeoNeo | 2024-01-01..2024-12-31 | $628.18K |
| 2025-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYr; ExecutiveCategory: NonPeoNeo | 2024-01-01..2024-12-31 | -$2.13M |
| 2025-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYr; ExecutiveCategory: NonPeoNeo | 2024-01-01..2024-12-31 | $0.00 |
| 2025-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYr; ExecutiveCategory: NonPeoNeo | 2024-01-01..2024-12-31 | $0.00 |
| 2025-04-30 DEF 14A | Peer Group Issuers Footnote | 2024-01-01..2024-12-31 | 6. Represents the weighted peer group TSR, weighted according to the respective companies’ stock market capitalization at the beginning of each period for which a return is indicated. The peer group used for this purpose is the following published industry index: Nasdaq Biotechnology Index. | |
| 2025-04-30 DEF 14A | Compensation Actually Paid Vs Total Shareholder Return | 2024-01-01..2024-12-31 | Relationship Between PEO and Non-PEO NEO Compensation Actually Paid, Company TSR and Cumulative TSR Comparison As demonstrated by the following graph, the amount of compensation actually paid to our PEO and the average amount of compensation actually paid to our other NEOs as a group (except Dr. Kum… | |
| 2025-04-30 DEF 14A | Total Shareholder Return Vs Peer Group | 2024-01-01..2024-12-31 | Relationship Between PEO and Non-PEO NEO Compensation Actually Paid, Company TSR and Cumulative TSR Comparison As demonstrated by the following graph, the amount of compensation actually paid to our PEO and the average amount of compensation actually paid to our other NEOs as a group (except Dr. Kum… | |
| 2025-04-30 DEF 14A | Compensation Actually Paid Vs Net Income | 2024-01-01..2024-12-31 | Relationship Between PEO and Non-PEO NEO Compensation Actually Paid and Net Loss The following chart sets forth the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our Non-PEO NEOs, and our net loss during the five most recently completed fisc… | |
| 2025-04-30 DEF 14A | Compensation Actually Paid Vs Company Selected Measure | 2024-01-01..2024-12-31 | Relationship Between PEO and Non-PEO NEO Compensation Actually Paid and Revenue The following chart sets forth the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our Non-PEO NEOs, and our Revenue during the five most recently completed fiscal… | |
| 2025-04-30 DEF 14A | Tabular List Table | 2024-01-01..2024-12-31 | Table of Performance Measures As discussed in greater detail in the “Executive Compensation – Compensation Discussion and Analysis,” the actual amount of bonus compensation that is earned by our NEOs is a discretionary determination made by the Board of Directors based on the recommendation of the C… | |
| 2025-04-30 DEF 14A | Additional402v Disclosure | 2024-01-01..2024-12-31 | Pay Versus Performance: Conclusions The Compensation Committee believes in “pay for performance” and has structured our compensation program to reward our executive officers when we are delivering strong results. As discussed in more detail in “2024 Business and Financial Highlights”, the approval o… | |
| 2025-04-29 10-Q | Material Terms Of Trading Arrangement | 2025-01-01..2025-03-31 | On March 31, 2025 , Thomas Trimarchi , our President and Chief Financial Officer , adopted a trading plan (the “Trimarchi Trading Plan”) intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). The Trimarchi Trading Plan provides for the potential sale of a m… | |
| 2025-02-20 10-K | Material Terms Of Trading Arrangement | 2024-10-01..2024-12-31 | Rule 10b5-1 Trading Plans Note : The following table discloses any officer (as defined in Rule 16a-1(f) under the Exchange Act) or director who entered into, modified or terminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regu… |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |